FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b). Check this box to indicate that a

may continue. *See*Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| 1. Name and Address of Reporting Person * Drapé Eric | 2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [TEVA] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below) Other (specify below) | | | |
|---|---|--|--|--|--|
| (Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St., | 3. Date of Earliest Transaction (Month/Day/Year) 02/16/2024 | Executive VP Global Operations | | | |
| (Street) Tel Aviv, L3 6944020 | 4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person Form filed by More than One Reporting Person | | | |
| (City) (State) (Zip) | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1.Title of Security | 2. Transaction | 2A. Deemed | 3. Transaction | | 4. Securities Acquired (A) | | | 5. Amount of Securities | 6. | 7. Nature |
|---------------------|------------------|--------------------|----------------|---|----------------------------|-----|------------|------------------------------|-------------|-------------|
| (Instr. 3) | Date | Execution Date, if | Code | | or Disposed of (D) | |)) | Beneficially Owned Following | Ownership | of Indirect |
| | (Month/Day/Year) | any | (Instr. 8) | | (Instr. 3, 4 and 5) | | | Reported Transaction(s) | Form: | Beneficial |
| | | (Month/Day/Year) | | | | | | (Instr. 3 and 4) | Direct (D) | Ownership |
| | | | | | | (A) | | | or Indirect | (Instr. 4) |
| | | | | | | or | | | (I) | |
| | | | Code | V | Amount | (D) | Price | | (Instr. 4) | |

| Ordinary Shares (1) 02/16/2024 | S | 173,261 | D I | \$ 13.0549 (2) | 1 (3) | D | | |
|--------------------------------|---|---------|-----|----------------------|-------|---|--|--|
|--------------------------------|---|---------|-----|----------------------|-------|---|--|--|

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| D S | Title of derivative ecurity extr. 3) | Conversion | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | Code | | | ative ities | 6. Date Exer and Expiration (Month/Day) | on Date /Year) | Amor Unde Secur | ele and unt of orlying rities : 3 and 4) | Derivative Security (Instr. 5) | Securities Beneficially | 10. Ownership Form of Derivative Security: | Beneficial |
|--------|--------------------------------------|------------|--------------------------------------|---|------|---|------------------------------------|----------------|---|--------------------|-----------------------|--|--------------------------------------|---|--|------------|
| | | Security | | | | | (A) or Dispo of (D) (Instr. and 5) | sed 3, 4, | | | | , | | Following Reported Transaction(s) (Instr. 4) | Direct (D) or Indirect (I) (Instr. 4) | |
| | | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | little | Amount or Number of Shares | | | | |

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.01 to \$13.15, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. Number of shares rounded to the nearest whole share.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Eric Drape 02/21/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.